Clinical trials: Diabetes, Type 1
Type 1 Diabetes, Type2diabetes
Liom Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)
This is a single-centre, multiple cohort, open study.
- Trial name
- NCT06272136
- Testing
- Clinical Demo 2.0
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Liom Health AG
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
This study is to investigate the effects of Fiasp®, a mealtime insulin, in patients with diabetes mellitus. The purpose of this study is to collect information about Fiasp®, which is prescribed to the participants by their…
- Trial name
- NCT03987802
- Testing
- Faster-acting insulin aspart
- Where
- 36 sites in India
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Europe, Oceania, and the United States of America (USA). The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart…
- Trial name
- BOOST™ (NCT00978627)
- Testing
- insulin degludec/insulin aspart, insulin detemir, insulin aspart
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 548 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689
This trial is conducted in Europe. The aim of this research is to assess the safety of continuous treatment with insulin detemir following participation in trial NN304-1689 (NCT00435019) on antibody development.
- Trial name
- NCT00623194
- Testing
- insulin detemir, insulin aspart
- Where
- 32 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 146 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Fr1da Early Diagnosis and Care of Type 1 Diabetes
The Fr1da study: "Early diagnosis and care of type 1 diabetes" aims to carry out a comprehensive, population-based screening for the early diagnosis of type 1 diabetes as part of the U7 to U11 preventive medical check-up for…
- Trial name
- Fr1da (NCT04039945)
- Where
- Germany
- Volunteers
- 285,000 people, healthy volunteers welcome
- Sponsor
- Helmholtz Zentrum München
Diabetes, Hypoglycemia
Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus
The purpose of this study is to determine the safety of BHT-3021 injections given weekly for 12 weeks and to evaluate the effect of BHT-3021 on antibody and immune (T cell) responses to autoantigens (e.g. insulin).
- Trial name
- NCT00453375
- Testing
- BHT-3021
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 80 people
- Sponsor
- Bayhill Therapeutics
Diabetes Mellitus, Type 1
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump
The study is looking at the effect and safety of a new fast-acting insulin (NNC0471 0119) to people with type 1 diabetes when given by an insulin pump.
- Trial name
- NCT06809621
- Testing
- NNC0471-0119 H, Insulin aspart
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy
Study B1621018 will assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Dose Levels of Pf-04937319 in Japanese Subjects with Type 2 Diabetes Mellitus As Monotherapy
- Trial name
- NCT02292433
- Testing
- PF-04937319 high dose, PF-04937319 low dose
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Type 2 Diabetes
A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes
The study is to assess the safety, pharmacokinetics, and pharmacodynamic profile of HMS1005 in patient with diabetes
- Trial name
- NCT07568678
- Testing
- HMS1005
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Hua Medicine Limited
Pancreatic Cancer
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other…
- Trial name
- EXCEED (NCT05663515)
- Testing
- Exenatide, Non-GLP-1 RA based glucose lowering drugs
- Where
- 8 sites in Denmark, Finland and 5 more
- Volunteers
- 24,000 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin
This trial is conducted in Europe. The aim of this trial is to compare two insulin delivery pens in the everyday life setting of patients with diabetes treated with insulin.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00569998
- Testing
- NovoPen™ 4, NovoPen® 3
- Where
- 23 sites in Austria, Germany and 3 more
- Volunteers
- 208 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus
This study is looking at how five different formulations of faster aspart 200 U/mL reach and stay in the blood after injection. The purpose is to find a formulation that behaves similarly to the reference product called faster…
- Trial name
- NCT03723759
- Testing
- Faster Aspart 200 U/mL, Faster aspart 100 U/mL
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified…
- Trial name
- ABACUS (NCT01460446)
- Testing
- Aviva Expert blood glucose meter, Aviva Nano blood glucose meter
- Where
- 33 sites in Germany, United Kingdom
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes Mellitus
To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus
This is a double-blind, randomised, controlled, two period crossover phase Ib trial using an individualized standard meal with a fixed nutrient ratio in subjects with type 1 diabetes mellitus to investigate postprandial blood…
- Trial name
- NCT02528396
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Adocia
Type 1 Diabetes Mellitus
A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus
The main purpose of this study is to evaluate the effect of excipients sodium citrate and treprostinil without insulin on local infusion site pain in participants with type 1 diabetes mellitus (T1DM) on continuous subcutaneous…
- Trial name
- NCT05067270
- Testing
- Sodium Citrate, Treprostinil, Humalog diluent
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.
- Trial name
- NCT07073170
- Testing
- LY3549492
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Obesity
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis
- Trial name
- XW003 (NCT04389775)
- Testing
- Cohort A, Cohort B
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Type 2 Diabetic Nephropathy
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845…
- Trial name
- NCT01488877
- Testing
- PF-03882845, Spironolactone
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pfizer
Type 1 Diabetes Mellitus
Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting
The purpose of this study is to evaluate the performance of an insulin pump controlling algorithm while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.
- Trial name
- NCT01401751
- Testing
- Hypoglycemia-Hyperglycemia Minimizer System
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Animas Corporation